Hypericin

Phase 3Small molecule

SSoligenix

Hypericin is one of 113 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous T-Cell LymphomaActive, not recruiting

Mycosis FungoidesTerminated

PsoriasisActive, not recruiting

Cutaneous T-Cell LymphomaPhase 2

Active, not recruiting

Mycosis FungoidesPhase 3

Terminated

PsoriasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Stelara

Johnson & Johnson

Preclinical

37 3

Hypericin

SSoligenix

Phase 3

1 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mycosis Fungoides2 trials

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Completed·—·Phase 2·NCT05872854·10 enrolled

A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Terminated·SSoligenix·Phase 3·NCT06470451·70 enrolled

Psoriasis1 trial

Topical SGX302 for Mild-to-Moderate Psoriasis

Completed·SSoligenix·Phase 2·NCT05442190·15 enrolled

Treatment1 trial

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Completed·SSoligenix·Phase 2·NCT06149247·10 enrolled

Oral1 trial

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000792·24 enrolled

Cutaneous T-cell lymphoma1 trial

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Completed·SSoligenix·Phase 2·NCT05380635·9 enrolled

1 more indication

HIV1 trial

A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000645·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Hypericin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hypericin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hypericin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Soligenix company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSoligenix

Hypericin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mycosis Fungoides2 trials

Psoriasis1 trial

Treatment1 trial

Oral1 trial

Cutaneous T-cell lymphoma1 trial

HIV1 trial

References

Drug Info

Quick Facts

Related News